What is Precision Diagnostics?
Founded in 2011 and headquartered in San Diego, California, Precision Diagnostics operates at the forefront of clinical urine and oral fluid drug testing. The company is recognized for its ultra-high sensitivity testing capabilities, addressing critical needs in healthcare and forensic toxicology. Its focus on advanced diagnostic solutions positions it as a key player in a rapidly evolving market.
How much funding has Precision Diagnostics raised?
Precision Diagnostics has raised a total of $16.5M across 2 funding rounds:
Debt
$14.5M
Debt
$2M
Debt (2015): $14.5M with participation from BelHealth Investment Partners
Debt (2020): $2M led by PPP
Key Investors in Precision Diagnostics
BelHealth Investment Partners
BelHealth Investment Partners is a premier growth partner focused on building healthcare businesses. With $328 million in assets under management, they typically invest between $20 million and $50 million per platform. The firm has extensive experience, having completed over 50 transactions valued at approximately $1 billion. Their services cater to various sectors within the healthcare industry.
PPP
Public-Private Partnership
What's next for Precision Diagnostics?
The recent major strategic investment signals a pivotal phase for Precision Diagnostics, likely enabling expansion of its testing services, enhancement of its technological infrastructure, and broader market penetration. This capital infusion is expected to fuel further innovation and solidify its competitive advantage in the high-sensitivity drug testing arena. The company's trajectory suggests a focus on scaling operations and potentially exploring new applications for its advanced diagnostic technologies.
See full Precision Diagnostics company page
